Palisade Bio Inc PALI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PALI is a good fit for your portfolio.
News
-
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)
-
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach
-
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool
-
Palisade Bio to Participate in the Virtual Investor Lunch Break Event
-
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™
-
Palisade Bio Announces 1-for-15 Reverse Stock Split
-
Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update
-
Palisade Bio to Present at Digestive Disease Week (DDW) 2024
Trading Information
- Previous Close Price
- $6.03
- Day Range
- $6.36–9.09
- 52-Week Range
- $3.82–36.60
- Bid/Ask
- $7.11 / $7.24
- Market Cap
- $6.03 Mil
- Volume/Avg
- 12.3 Mil / 1.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 11.00
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 9
- Website
- https://www.palisadebio.com
Valuation
|
Metric
|
PALI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.33 |
Price/Sales | 11.00 |
Price/Cash Flow | — |
Price/Earnings
PALI
Financial Strength
|
Metric
|
PALI
|
|---|---|
Quick Ratio | 4.86 |
Current Ratio | 5.15 |
Interest Coverage | −819.00 |
Quick Ratio
PALI
Profitability
|
Metric
|
PALI
|
|---|---|
Return on Assets (Normalized) | −71.55% |
Return on Equity (Normalized) | −85.37% |
Return on Invested Capital (Normalized) | −82.51% |
Return on Assets
PALI
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rxptpqxw | Fzhm | $578.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lwrxwgmt | Jbwjm | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Txjsbzj | Kpdkbr | $99.5 Bil | |
MRNA
| Moderna Inc | Ttscxdzr | Wyb | $42.7 Bil | |
ARGX
| argenx SE ADR | Chqsqrpxq | Nfm | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Rhnzlcpsf | Pns | $21.4 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Yywjpzl | Szpjfc | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dtvkmyrw | Njqvtpz | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Shfjpxwgd | Vcwmjx | $12.7 Bil | |
INCY
| Incyte Corp | Qdxzmyvzz | Lzxfg | $11.9 Bil |